These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16355016)

  • 21. [Chronic kidney disease (CKD) as an independent risk factor for cardiovascular disease (CVD)].
    Minami J; Ishimitsu T; Sudo Y; Matsuoka H
    Nihon Rinsho; 2008 Sep; 66(9):1657-63. PubMed ID: 18788391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease.
    Vaziri ND
    Clin Exp Nephrol; 2014 Apr; 18(2):265-8. PubMed ID: 23974528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endothelial dysfunction and chronic kidney disease: treatment options.
    Wu-Wong JR
    Curr Opin Investig Drugs; 2008 Sep; 9(9):970-82. PubMed ID: 18729004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic kidney disease, dyslipidemia, and atherosclerosis.
    Shoji T; Abe T; Matsuo H; Egusa G; Yamasaki Y; Kashihara N; Shirai K; Kashiwagi A;
    J Atheroscler Thromb; 2012; 19(4):299-315. PubMed ID: 22166970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiometabolic syndrome and chronic kidney disease: what is the link?
    Sarafidis PA; Whaley-Connell A; Sowers JR; Bakris GL
    J Cardiometab Syndr; 2006; 1(1):58-65. PubMed ID: 17675896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-alcoholic fatty liver disease and dyslipidemia: An update.
    Katsiki N; Mikhailidis DP; Mantzoros CS
    Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD.
    Dogra G; Irish A; Chan D; Watts G
    Am J Kidney Dis; 2006 Dec; 48(6):926-34. PubMed ID: 17162147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
    Simon TG; Corey KE; Chung RT; Giugliano R
    Dig Dis Sci; 2016 Dec; 61(12):3425-3435. PubMed ID: 27714510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The progression of cardiovascular risk to cardiovascular disease.
    Rosin BL
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S3-8. PubMed ID: 17934392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Inflammation, oxidative stress and kidney function in arterial hypertension].
    Cerasola G; Guarneri M; Cottone S
    G Ital Nefrol; 2009; 26 Suppl 46():8-13. PubMed ID: 19644813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Statins and kidney disease].
    Bigazzi R; Grimaldi D; Bianchi S
    G Ital Nefrol; 2012; 29(2):160-73. PubMed ID: 22538946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Dyslipidemia as a therapeutic target for prevention of cardiovascular events and end-stage renal disease].
    Watanabe T
    Nihon Rinsho; 2008 Sep; 66(9):1761-9. PubMed ID: 18788407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A lethal tetrad in diabetes: hyperglycemia, dyslipidemia, oxidative stress, and endothelial dysfunction.
    Yu Y; Lyons TJ
    Am J Med Sci; 2005 Nov; 330(5):227-32. PubMed ID: 16284482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Obesity and metabolic syndrome as related to cardiovascular disease.
    Nikolopoulou A; Kadoglou NP
    Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):933-9. PubMed ID: 22908926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outline of the report on cardiovascular disease in China, 2010.
    Hu SS; Kong LZ; Gao RL; Zhu ML; Wang W; Wang YJ; Wu ZS; Chen WW; Liu MB;
    Biomed Environ Sci; 2012 Jun; 25(3):251-6. PubMed ID: 22840574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease.
    Matsubara K; Stenvinkel P; Qureshi AR; Carrero JJ; Axelsson J; Heimbürger O; Bárány P; Alvestrand A; Lindholm B; Suliman ME
    J Nephrol; 2009; 22(6):774-82. PubMed ID: 19967657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endothelium-dependent vasodilation and oxidative stress in chronic renal failure: impact on cardiovascular disease.
    Annuk M; Zilmer M; Fellström B
    Kidney Int Suppl; 2003 May; (84):S50-3. PubMed ID: 12694308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insights into the molecular mechanisms of diabetes-induced endothelial dysfunction: focus on oxidative stress and endothelial progenitor cells.
    Saad MI; Abdelkhalek TM; Saleh MM; Kamel MA; Youssef M; Tawfik SH; Dominguez H
    Endocrine; 2015 Dec; 50(3):537-67. PubMed ID: 26271514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of dyslipidemia and oxidative stress on vasoactive mediators in patients with renal dysfunction.
    Jabarpour M; Rashtchizadeh N; Argani H; Ghorbanihaghjo A; Ranjbarzadhag M; Sanajou D; Panah F; Alirezaei A
    Int Urol Nephrol; 2019 Dec; 51(12):2235-2242. PubMed ID: 31641998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between insulin resistance and the development of cardiovascular disease.
    Ormazabal V; Nair S; Elfeky O; Aguayo C; Salomon C; Zuñiga FA
    Cardiovasc Diabetol; 2018 Aug; 17(1):122. PubMed ID: 30170598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.